Affordable and Safe Prescription Drug Importation Act of 2025
U.S. Congress · HR3162 ·
What the bill says
Introduced 2025-05-01. Latest action: Referred to the House Committee on Energy and Commerce.
Summary (plain-language)
Affordable and Safe Prescription Drug Importation Act of 2025 This bill expands the categories of prescription drugs that may be imported into the United States and the countries from which such drugs may be imported. Current law allows the Department of Health and Human Services (HHS) to authorize importation of certain eligible prescription drugs from Canada if HHS certifies that doing so would pose no additional risk to public health and safety, among other requirements. HHS long declined to make the requisite certification, citing safety concerns (e.g., contamination, counterfeiting), but ultimately made the certification in 2020 and has since approved one state plan to import drugs. The bill removes the certification requirement and requires HHS to issue regulations that permit importation of qualifying prescription drugs from the United Kingdom, Switzerland, and member states of the European Union, in addition to Canada. After one year, if HHS determines that importation of drugs from these countries has been conducted safely, HHS may authorize importation from other countries that meet certain requirements. The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin. Further, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS. Finally, the bill imposes criminal penalties for websites that sell counterfeit drugs or dispense drugs without a required prescription.
Sponsors
- Janice D. Schakowsky (primary)
- Yassamin Ansari
- Steve Cohen
- Lloyd Doggett
- Ilhan Omar
- Chellie Pingree
- Mark Pocan
Text versions
- Introduced in House — 2025-05-01 — XML
What analysts say
No nonpartisan analysis on file for this measure yet.
What politicians say
No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.
Action History
| Date | Action |
|---|---|
| 2025-05-01 | Introduced in House |
| 2025-05-01 | Referred to the House Committee on Energy and Commerce. |
Lobbying on this bill
Showing 2 of 2 bill mentions.
Honesty note: each filer below disclosed lobbying on this bill — that much the filing tells us. But the dollar figure is their total lobbying spend for the whole quarter across all their issues, not the amount spent on this bill, and the filing never says whether they supported or opposed it.
| Registrant (lobbying firm) | Client | Period | Reported quarterly amount | Extraction |
|---|---|---|---|---|
| ALLIANCE FOR RETIRED AMERICANS | ALLIANCE FOR RETIRED AMERICANS | Q2 2026 | $85,000 | |
| ALLIANCE FOR RETIRED AMERICANS | ALLIANCE FOR RETIRED AMERICANS | Q1 2026 | $95,000 |
Source: Senate LDA filings.